David Gitlin concentrates his practice in the areas of corporate acquisitions and divestitures, venture capital and technology development, and corporate finance. He has an extensive practice representing foreign clients doing business in the United States and U.S. clients doing business abroad. Mr. Gitlin has handled more than 200 M&A transactions, of which more than 100 have been cross-border transactions. Among Mr. Gitlin's clients are leading companies in Finland, India, Israel and Sweden. He represents numerous foreign clients in the purchase or sale of U.S. businesses and has represented U.S. clients in the purchase or sale of businesses in approximately 15 different countries. Mr. Gitlin is recognized by both Chambers USA and The Legal 500 as a leading M&A attorney. Chambers notes "he wins plaudits as a 'highly skilled negotiator and successful deal-maker'" and recognizes his "especially high profile in M&A and venture capital." The 2008 edition of The Legal 500 referring to Mr. Gitlin as "a major figure in M&A." Mr. Gitlin has represented emerging growth companies in various industries, including: ˇ biotechnology ˇ medical devices ˇ wellness ˇ information technology ˇ software, security ˇ alternative energy Mr. Gitlin also represents both U.S. and foreign venture capital funds. Mr. Gitlin has handled numerous technology development transactions, particularly in the life sciences area. These include drug development, licensing and joint venture agreements involving biotech and big pharma as well as collaborations between industry and academia. In January 2005, Mr. Gitlin received parallel citations from the Mayors of Philadelphia and Tel-Aviv for exceptional accomplishments in developing business opportunities for Israeli companies in the United States. Mr. Gitlin has written and lectured on a variety of legal topics, including corporate acquisitions, exit strategies, going-private transactions, negotiating strategies, venture capital and the Sarbanes-Oxley Act. Mr. Gitlin is fluent in Hebrew and Spanish. Representative Matters ˇ Leading publicly traded Finnish manufacturing company in its acquisition of a division of a large U.S. company. The acquisition involved the purchase of stock and assets of subsidiaries located in the United States and five foreign countries, and the coordination of closings in different countries across different calendar years. ˇ Leading multinational publicly traded Swedish manufacturing company in its acquisition of a division of a Fortune 500 company. The acquisition involved the purchase of stock and assets of subsidiaries located in 12 different countries. Mr. Gitlin coordinated 13 simultaneous closings throughout the globe. ˇ Leading multinational publicly traded Indian company in the acquisition of a California corporation. The transaction included particularly complex regulatory matters specific to the defense industry as well as cross-border employee benefit issues. ˇ A NASDAQ-traded CRO in the acquisition of a Finnish corporation for a combination of cash and stock. The transaction involved complex cross-border securities issues. ˇ An Israel-based provider of application problem resolution software in its acquisition by a large U.S. software company. Mr. Gitlin structured and negotiated a complex stock purchase agreement that incorporated the use of a novel statutory "take along" provision. ˇ An Israel-based leading manufacturer of armored equipment in its acquisition of a Michigan-based defense contractor. ˇ Leading Mid-Atlantic late-stage venture fund in an investment in a rapidly expanding provider of medical market research. ˇ U.S.-based biotech company in a Series B round investment that was led by a Swiss-based, global life sciences fund and a leading life sciences, California-based investment firm. ˇ Swiss-based, global life sciences fund in a Series B investment in a biotechnology company engaged in the development of novel products for the treatment of metabolic diseases. ˇ U.S.-based corporation engaged in the development of alternative energy sources in a significant investment by a leading Israeli private equity fund. ˇ Israeli-based biotech company in a worldwide license and distribution agreement with a leading Italian pharma company. Community Service & Affiliations Mr. Gitlin is a past president of America-Israel Chamber of Commerce, Mid-Atlantic Chapter. Mr. Gitlin received the Distinguished Humanitarian Award from the Bnai Zion Foundation in 2010. Memberships American Bar Association International Bar Association Pennsylvania Bar Association Philadelphia Bar Association Union Internationale des Advocats Events HOW TO LEVERAGE YOUR WORK EXPERIENCE INTO PRIVATE COMPANY OWNERSHIP
[Event]
Marvin Comisky Conference Center
Blank Rome LLP, One Logan Square, 130 North 18th Street
Philadelphia, PA 19013
March 8, 2011
David Gitlin and Beth Cohen PLANNING AN IPO? ISRAEL IPO SEMINAR
[Event]
Tel Aviv Hilton, Independence Park, Tel Aviv, Israel 63405
January 28, 2010
David Gitlin, Emanuel J. Adler and Frederick D. Lipman Publications BEING A U.S. PUBLIC COMPANY
[Book]
Bowne & Co., Inc.
February 2010
Christin R. Cerullo, David Gitlin, Frederick D. Lipman, Yelena M. Barychev, Ephraim Schmeidler and Barbara D. Linney News SPOTLIGHT ON THE ISRAEL VENTURE CONFERENCE
[Media Coverage]
November 4, 2009
David Gitlin and Beth Cohen FORMER WOLFBLOCK CORPORATE/SECURITIES PRACTICE CHAIR JOINS BLANK ROME
[Press Release]
April 2, 2009
David Gitlin, Ephraim Schmeidler and Shaun Snitman
Three New Additions to Corporate Practice Bolster Firm's International Capabilities Cases and Deals TOP IMAGE SYSTEMS IN A $2.85 MILLION PRIVATE PLACEMENT
[Deal]
June 13, 2011
David Gitlin, Ephraim Schmeidler and Yelena M. Barychev
Top Image Systems Ltd. in a $2.85 million private placement of stock to institutional investors. DEVELOPER OF ALTERNATE ENERGY SOURCES IN A $10 MILLION PRIVATE ISSUANCE
[Deal]
December 10, 2010
David Gitlin and Shaun Snitman
A U.S.-based company engaged in the development of alternate energy sources, in a private issuance of up to $10 million in convertible debt to a leading Israeli private equity fund. EUROPEAN INDUSTRIAL COMPANY ACQUIRES ENGINEERING SERVICE PROVIDER
[Deal]
January 2010
David Gitlin and Ephraim Schmeidler
A publicly-traded European industrial company in its acquisition of a leading engineering service provider on the North American market. MENTORTECH VENTURES IN A $3.3M SERIES C INVESTMENT IN MOLECULAR DETECTION, INC.
[Deal]
June 12, 2009
David Gitlin and Ephraim Schmeidler
MentorTech Ventures II, LP, an early-stage venture capital fund, as the lead investor in an up to $3.3 million Series C investment in Molecular Detection, Inc. PHYTOMEDICS, INC. CLOSES SERIES C FINANCING ROUND
[Deal]
April 30, 2009
David Gitlin and Shaun Snitman
Phytomedics, Inc. Closes Series C Financing Round CODAN LIMITED, AN AUSTRALIAN PUBLICLY TRADED COMPANY, ACQUIRES LOCUS MICROWAVE, INC.
[Deal]
April 30, 2009
David Gitlin, Barbara D. Linney and Ephraim Schmeidler
Codan Limited, an Australian Publicly Traded Company, acquires Locus Microwave, Inc., for an aggregate value of $4 million. Recognition CHAMBERS USA 2011 RECOGNIZES MORE BLANK ROME ATTORNEYS AND PRACTICES
[Ranking]
June 10, 2011
Thomas H. Belknap, Jr., Thomas E. Biron, Fred Blume, J. Caleb Boggs III, Kevin J. Bruno, David W. Carickhoff, et al. CHAMBERS USA 2010 RECOGNIZES MORE BLANK ROME ATTORNEYS AND PRACTICES
[Ranking]
June 11, 2010
Thomas H. Belknap, Jr., Thomas E. Biron, Fred Blume, Ernest W. Chung, Scott F. Cooper, Steven Dubow, et al. CHAMBERS USA 2009 RECOGNIZES MORE BLANK ROME ATTORNEYS AND PRACTICES
[Ranking]
June 2009
Thomas H. Belknap, Jr., Thomas E. Biron, Fred Blume, Scott F. Cooper, Steven Dubow, Bonnie Glantz Fatell, et al. |